公开(公告)号：US20240252647A1

公开(公告)日：2024-08-01

申请号：US18456612

申请日：2023-08-28

申请人： Journey Medical Corporation

发明人： Dov Tamarkin ,  Elana Gazal ,  Yohan Hazot ,  David Schuz ,  Irakliy Papiashvili

IPC分类号： A61K47/44 ,  A61K8/31 ,  A61K8/34 ,  A61K8/36 ,  A61K9/00 ,  A61K9/12 ,  A61K31/137 ,  A61K31/192 ,  A61K31/4164 ,  A61K31/57 ,  A61K31/573 ,  A61K31/593 ,  A61K31/65 ,  A61K45/06 ,  A61K47/02 ,  A61K47/06 ,  A61K47/10 ,  A61K47/12 ,  A61K47/24 ,  A61Q17/04 ,  A61Q19/00 ,  A61Q19/10

CPC分类号： A61K47/44 ,  A61K8/31 ,  A61K8/342 ,  A61K8/361 ,  A61K9/0014 ,  A61K9/0048 ,  A61K9/12 ,  A61K9/122 ,  A61K9/124 ,  A61K31/137 ,  A61K31/192 ,  A61K31/4164 ,  A61K31/57 ,  A61K31/573 ,  A61K31/593 ,  A61K31/65 ,  A61K45/06 ,  A61K47/02 ,  A61K47/06 ,  A61K47/10 ,  A61K47/12 ,  A61K47/24 ,  A61Q17/04 ,  A61Q19/00 ,  A61Q19/10 ,  A61K2800/31 ,  A61K2800/33

摘要： The present disclosure relates generally to compositions for cosmetic or pharmaceutical application. The compositions include a carrier and rheology modulators.APP

公开(公告)号：US20240226006A1

公开(公告)日：2024-07-11

申请号：US18425676

申请日：2024-01-29

申请人： Covis Pharma GmbH

发明人： Helgert Müller ,  Renate Engelstätter ,  Ulrich Bildmann ,  Andrea Bauer ,  Paul McGlynn

IPC分类号： A61K9/12 ,  A61K9/00 ,  A61K31/58 ,  A61M11/04 ,  A61M15/00

CPC分类号： A61K9/124 ,  A61K9/008 ,  A61K31/58 ,  A61M11/04 ,  A61M15/0001 ,  A61M15/0065 ,  A61M15/009

摘要： This invention relates to a pharmaceutical aerosol product suitable for administration by oral or nasal inhalation and its use in the treatment of respiratory diseases, in particular in the treatment of children. The aerosol composition comprises ciclesonide, ethanol and either 1,1,1,2-tetrafluoroethane, or 1,1,1,2,3,3,3-heptafluoropropane.

公开(公告)号：US11980646B2

公开(公告)日：2024-05-14

申请号：US16344630

申请日：2017-10-27

申请人： YUN NV ,  Universiteit Antwerpen

发明人： Tim Henkens ,  Filip Kiekens ,  Sarah Lebeer ,  Ingmar Claes

IPC分类号： A61K9/00 ,  A61K9/12 ,  A61K35/744 ,  A61K47/24

CPC分类号： A61K35/744 ,  A61K9/0014 ,  A61K9/12 ,  A61K9/124 ,  A61K47/24

摘要： Aerosol sprays are provided that include one or more bacterial species and at least one siloxane suitable for applying said one or more bacterial species to a surface or into the environment. Such sprays may also include a propellant under pressure. Such aerosol sprays may be used for restoring or maintaining a healthy skin microbiota.

公开(公告)号：US20240091152A1

公开(公告)日：2024-03-21

申请号：US18519851

申请日：2023-11-27

申请人： The Materia Company Limited

发明人： Matthaios VIDALIS

IPC分类号： A61K9/12 ,  A61K9/00 ,  A61K9/14 ,  A61K31/4164 ,  A61K31/4706 ,  A61K31/69 ,  A61K33/22 ,  A61P15/00 ,  A61P15/02

CPC分类号： A61K9/124 ,  A61K9/0034 ,  A61K9/12 ,  A61K9/143 ,  A61K9/145 ,  A61K9/146 ,  A61K9/148 ,  A61K31/4164 ,  A61K31/4706 ,  A61K31/69 ,  A61K33/22 ,  A61P15/00 ,  A61P15/02

摘要： An intravaginal formulation comprising a dry powder composition and propellant(s) and the apparatus capable of delivery intravaginally a dry powder composition.

公开(公告)号：US20240066101A1

公开(公告)日：2024-02-29

申请号：US18486860

申请日：2023-10-13

申请人： Emory University

发明人： Giacomo Waller ,  Yiwen Li ,  Edmund Waller

IPC分类号： A61K38/26 ,  A61K9/00 ,  A61K9/12 ,  A61K47/24 ,  A61K47/69

CPC分类号： A61K38/26 ,  A61K9/0075 ,  A61K9/124 ,  A61K47/24 ,  A61K47/6935

摘要： In certain embodiments, this disclosure relates to VIP and VIP agonists, optionally conjugated to nanoparticles, for use in methods of treating inflammatory T cell-mediated diseases or conditions, e.g., treating or preventing GvHD. In certain embodiments, this disclosure relates to methods of pulmonary administration of VIP and VIP agonists, optionally conjugated to nanoparticles. In certain embodiments, this disclosure contemplates nanoparticles disclosed herein.

公开(公告)号：US20240059713A1

公开(公告)日：2024-02-22

申请号：US18547958

申请日：2022-02-24

申请人： SYNESIS LLC

发明人： Jess D. REED ,  Daniel Alfredo ESQUIVEL-ALVARADO ,  Emilia ALFARO-VIQUEZ ,  Christian G. KRUEGER

IPC分类号： C07D519/00 ,  A61K9/20 ,  A61K9/48 ,  A61K9/00 ,  A61K9/12 ,  A61K9/06 ,  G01N33/569

CPC分类号： C07D519/00 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/4866 ,  A61K9/4858 ,  A61K9/485 ,  A61K9/0019 ,  A61K9/124 ,  A61K9/06 ,  G01N33/56916 ,  G01N2333/245 ,  G01N2469/10

摘要： Proanthocyanidin-cinnamaldehydes pyrylium products (FP) were synthesized by the condensation reaction of proantho-cyanidins (PAC) with various cinnamaldehydes. Synthesized FP exhibited fluorescence at higher excitation and emission wavelengths than PAC. FP were evaluated for their ability to agglutinate extra-intestinal pathogenic Escherichia coli (ExPEC). Results showed that FP were significantly more bioactive (p-value

公开(公告)号：US11883372B2

公开(公告)日：2024-01-30

申请号：US17694972

申请日：2022-03-15

申请人： MEXICHEM FLUOR S.A. DE C.V.

发明人： Stuart Corr ,  Timothy James Noakes

IPC分类号： A61K31/137 ,  A61K9/00 ,  A61K9/12 ,  A61K31/439 ,  A61K31/573 ,  A61K47/14 ,  A61K47/24 ,  A61K47/32 ,  A61K31/56 ,  A61K45/06 ,  A61P11/00

CPC分类号： A61K31/137 ,  A61K9/008 ,  A61K9/0078 ,  A61K9/124 ,  A61K31/439 ,  A61K31/56 ,  A61K31/573 ,  A61K45/06 ,  A61K47/14 ,  A61K47/24 ,  A61K47/32 ,  A61P11/00 ,  A61K31/56 ,  A61K2300/00 ,  A61K31/137 ,  A61K2300/00

摘要： A pharmaceutical composition is described. The composition comprises: (i) a drug component consisting of salmeterol xinafoate and fluticasone propionate. and (ii) a propellant component at least 90 wt % of which is 1,1-difluoroethane (HFA-152a). The drug component is the sole drug component in the pharmaceutical composition.

公开(公告)号：US11850304B2

公开(公告)日：2023-12-26

申请号：US17042555

申请日：2019-03-28

申请人： The Materia Company Limited

发明人： Matthaios Vidalis

IPC分类号： A61K9/12 ,  A61K9/00 ,  A61K9/14 ,  A61K31/4164 ,  A61K31/4706 ,  A61K31/69 ,  A61K33/22 ,  A61P15/00 ,  A61P15/02

CPC分类号： A61K9/124 ,  A61K9/0034 ,  A61K9/12 ,  A61K9/143 ,  A61K9/145 ,  A61K9/146 ,  A61K9/148 ,  A61K31/4164 ,  A61K31/4706 ,  A61K31/69 ,  A61K33/22 ,  A61P15/00 ,  A61P15/02

摘要： An intravaginal formulation comprising a dry powder composition and propellant(s) and the apparatus capable of delivery intravaginally a dry powder composition.

公开(公告)号：US20230381434A1

公开(公告)日：2023-11-30

申请号：US18327723

申请日：2023-06-01

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Hugh D.C. SMYTH ,  Robert O. WILLIAMS, III ,  Zachary WARNKEN ,  Yang LU

IPC分类号： A61M15/08 ,  G16H20/10 ,  G16H40/63 ,  A61K9/00 ,  A61K9/12 ,  A61K9/14 ,  A61K31/4184 ,  A61K47/32 ,  A61K49/00 ,  A61K49/06 ,  A61M31/00

CPC分类号： A61M15/08 ,  G16H20/10 ,  G16H40/63 ,  A61K9/0043 ,  A61K9/0085 ,  A61K9/122 ,  A61K9/124 ,  A61K9/146 ,  A61K31/4184 ,  A61K47/32 ,  A61K49/0043 ,  A61K49/06 ,  A61M31/005 ,  A61B5/055

摘要： Devices and methods for nasal administration of a pharmaceutical composition. In certain embodiments, the devices comprises a reservoir, a conduit in fluid communication with the reservoir, and an anatomic positioning device configured to position the conduit in a nasal cavity of a user. Particular embodiments include an actuator configured to transfer the pharmaceutical composition from the reservoir to the conduit and emit the pharmaceutical composition from the conduit.

公开(公告)号：US20230285728A1

公开(公告)日：2023-09-14

申请号：US18319769

申请日：2023-05-18

申请人： Frank Levy ,  Kimberley Levy

发明人： Frank Levy ,  Kimberley Levy

IPC分类号： A61M35/00 ,  A61M37/00 ,  A01N25/00 ,  A61M5/00 ,  A61M25/00 ,  A61B17/12 ,  A61M5/24

CPC分类号： A61M35/003 ,  A61M37/00 ,  A61M35/00 ,  A01N25/00 ,  A61M5/00 ,  A61M25/0071 ,  A61B17/12109 ,  A61B17/12186 ,  A61M5/2448 ,  A61K9/124

摘要： A medical fluid suspension generating apparatus for performing medical procedures includes a Venturi-agitating tip assembly composed of a multi-channel arrangement at a proximal first end thereof and a tip at a distal second end thereof. The apparatus also includes a compressed medical fluid unit fluidly connected to the multi-channel arrangement at a proximal first end of the Venturi-agitating tip assembly and a medical solution fluidly connected to the multi-channel arrangement at a proximal first end of the Venturi-agitating tip assembly. Pressurized sclerosant or other chemical medical solution, from the compressed medical fluid unit, and the medical solution of sclerosant or other chemical medical solution are combined within the Venturi-agitating tip assembly in a manner generating an enriched medical suspension that is ultimately dispensed from the suspension delivery apparatus to spray or wash the inner wall of a lumen.